{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:18:14Z","timestamp":1793373494602,"version":"4.5.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003484","name":"Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01224-9","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:02:49Z","timestamp":1649073769000},"page":"753-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management"],"prefix":"10.1016","volume":"19","author":[{"given":"Nik","family":"Krajnc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0614-6989","authenticated-orcid":false,"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10130","key":"10.1007\/s13311-022-01224-9_bib1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WCO.0000000000000206","article-title":"Classification, diagnosis, and differential diagnosis of multiple sclerosis","volume":"28","author":"Katz","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/ene.13669","article-title":"No evidence of disease activity - is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: An update","volume":"30","author":"Diaz","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-022-01224-9_bib5","doi-asserted-by":"crossref","unstructured":"Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996;6(3):109\u201319; quiz 120\u20131.","DOI":"10.1177\/090591999600600304"},{"issue":"12","key":"10.1007\/s13311-022-01224-9_bib6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cpt.547","article-title":"Therapeutic application of monoclonal antibodies in multiple sclerosis","volume":"101","author":"Orthmann-Murphy","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1007\/s13311-022-01224-9_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10072-010-0382-6","article-title":"The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases","volume":"31","author":"Bruno","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-022-01224-9_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6364","key":"10.1007\/s13311-022-01224-9_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/1352458510392263","article-title":"CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment","volume":"17","author":"Frisullo","year":"2011","journal-title":"Mult Scler"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1007\/s13311-022-01224-9_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-022-01224-9_bib16","doi-asserted-by":"crossref","unstructured":"Zhovtis Ryerson L, Li X, Goldberg JD, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7(2).","DOI":"10.1212\/NXI.0000000000000672"},{"key":"10.1007\/s13311-022-01224-9_bib17","doi-asserted-by":"crossref","unstructured":"Serra Lopez-Matencio JM, Perez Garcia Y, Meca-Lallana V, et al. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Front Neurol. 2021;12:716548.","DOI":"10.3389\/fneur.2021.716548"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1007\/s13311-022-01224-9_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips","year":"2011","journal-title":"Mult Scler"},{"issue":"16","key":"10.1007\/s13311-022-01224-9_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib24","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1007\/s00415-021-10559-w","article-title":"Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry","volume":"268","author":"Guger","year":"2021","journal-title":"J Neurol"},{"issue":"20","key":"10.1007\/s13311-022-01224-9_bib25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib27","unstructured":"European Medical Agency. Tysabri summary of product characteristics. 2009."},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01224-9_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-022-01224-9_bib30","doi-asserted-by":"crossref","unstructured":"Foley J, Defer G, Zhovtis Ryerson L, et al. Primary results of NOVA: a randomised controlled study of the efficacy of 6-week dosing of natalizumab versus continued 4-week treatment for multiple sclerosis, in ECTRIMS. 2021: Vienna.","DOI":"10.1016\/j.msard.2022.103626"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcph.1737","article-title":"Modeling the efficacy of natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended-interval dosing","volume":"61","author":"Chang","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-022-01224-9_bib33","doi-asserted-by":"crossref","unstructured":"Riancho J, Setien S, Sanchez de la Torre JR, et al. Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study. Front Immunol. 2021;12:614715.","DOI":"10.3389\/fimmu.2021.614715"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","article-title":"Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.20191","article-title":"Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.20193","article-title":"Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","article-title":"Disease activity return after natalizumab cessation in multiple sclerosis","volume":"16","author":"Rasenack","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-022-01224-9_bib39","doi-asserted-by":"crossref","unstructured":"Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339(5):285\u201391.","DOI":"10.1056\/NEJM199807303390501"},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2013-306054","article-title":"Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs","volume":"85","author":"Portaccio","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 6","key":"10.1007\/s13311-022-01224-9_bib41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1352458518816614","article-title":"Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria","volume":"26","author":"Bsteh","year":"2020","journal-title":"Mult Scler"},{"issue":"2\u20133","key":"10.1007\/s13311-022-01224-9_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1387\/ijdb.082773hs","article-title":"Receptor-mediated uptake and transport of macromolecules in the human placenta","volume":"54","author":"Schneider","year":"2010","journal-title":"Int J Dev Biol"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1423-0410.1971.tb04808.x","article-title":"Human IgG subclasses in maternal and fetal serum","volume":"21","author":"Morell","year":"1971","journal-title":"Vox Sang"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0002-9378(16)34434-9","article-title":"Fetal and maternal immunoglobulin levels during pregnancy","volume":"103","author":"Gusdon","year":"1969","journal-title":"Am J Obstet Gynecol"},{"key":"10.1007\/s13311-022-01224-9_bib46","doi-asserted-by":"crossref","unstructured":"Yeh WZ, Widyastuti PA, Van der Walt A, et al. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology. 2021.","DOI":"10.1212\/WNL.0000000000012084"},{"key":"10.1007\/s13311-022-01224-9_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the Tysabri(R) (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fneur.2020.00676","article-title":"Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab-A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry","volume":"11","author":"Guger","year":"2020","journal-title":"Front Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib51","article-title":"Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks","volume":"2016","author":"Alroughani","year":"2016","journal-title":"Mult Scler Int"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib52","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","article-title":"Humoral immune response to influenza vaccine in natalizumab-treated MS patients","volume":"34","author":"Vagberg","year":"2012","journal-title":"Neurol Res"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci Ther"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01224-9_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2014.03.035","article-title":"Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis","volume":"341","author":"Kaufman","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01224-9_bib56","doi-asserted-by":"crossref","unstructured":"Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581.","DOI":"10.2139\/ssrn.3886420"},{"key":"10.1007\/s13311-022-01224-9_bib57","doi-asserted-by":"crossref","unstructured":"Al Jumah M, Abulaban A, Aggad H, et al. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord. 2021;51:102925.","DOI":"10.1016\/j.msard.2021.102925"},{"key":"10.1007\/s13311-022-01224-9_bib58","doi-asserted-by":"crossref","unstructured":"Bsteh G, Hegen H, Traxler G, et al. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. Eur J Neurol. 2022.","DOI":"10.1111\/ene.15265"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib59","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","article-title":"Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab","volume":"100","author":"Buggins","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib60","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2006.05.006","article-title":"CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells","volume":"120","author":"Watanabe","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-022-01224-9_bib62","unstructured":"Lemtrada. Summary of product characteristics: Sanofi Belgium. 2020: Diegem, Belgium."},{"issue":"10","key":"10.1007\/s13311-022-01224-9_bib63","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/eji.1830181006","article-title":"Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies","volume":"18","author":"Bindon","year":"1988","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2567.1996.tb00003.x","article-title":"Recognition of CD52 allelic gene products by CAMPATH-1H antibodies","volume":"88","author":"Hale","year":"1996","journal-title":"Immunology"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib65","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib66","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"issue":"24","key":"10.1007\/s13311-022-01224-9_bib68","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/WNL.0000000000000520","article-title":"Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity","volume":"82","author":"Kousin-Ezewu","year":"2014","journal-title":"Neurology"},{"issue":"50","key":"10.1007\/s13311-022-01224-9_bib69","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1007\/s13311-022-01224-9_bib70","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","article-title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01224-9_bib71","doi-asserted-by":"crossref","unstructured":"Gross CC, Ahmetspahic D, Ruck T, et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e289.","DOI":"10.1212\/NXI.0000000000000289"},{"issue":"9856","key":"10.1007\/s13311-022-01224-9_bib72","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1007\/s13311-022-01224-9_bib73","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1007\/s13311-022-01224-9_bib74","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01224-9_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib77","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib78","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ Extension Study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-022-01224-9_bib79","doi-asserted-by":"crossref","unstructured":"Chan JK, Hernandez Martinez de Lapiscina E, Taylor C, et al. Long-term stability of neuroaxonal structure in alemtuzumab-treated relapsing-remitting multiple sclerosis patients. J Neuroophthalmol. 2020;40(1):37\u201343.","DOI":"10.1097\/WNO.0000000000000802"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib80","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/1352458518770085","article-title":"A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab","volume":"25","author":"Vavasour","year":"2019","journal-title":"Mult Scler"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1352458512444915","article-title":"Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab","volume":"19","author":"Button","year":"2013","journal-title":"Mult Scler"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib82","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/1352458519852093","article-title":"Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab","volume":"26","author":"Brown","year":"2020","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01224-9_bib83","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib84","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14712598.2018.1425388","article-title":"Alemtuzumab for the treatment of multiple sclerosis","volume":"18","author":"Evan","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-022-01224-9_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.msard.2017.07.019","article-title":"Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis","volume":"17","author":"Sega-Jazbec","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01224-9_bib87","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"10.1007\/s13311-022-01224-9_bib88","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Mult Scler"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib89","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","article-title":"Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis","volume":"17","author":"Buonomo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib90","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S1473-3099(14)70870-9","article-title":"The global burden of listeriosis: a systematic review and meta-analysis","volume":"14","author":"de Noordhout","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","article-title":"Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies","volume":"17","author":"Holmoy","year":"2017","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib92","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1352458520913277","article-title":"Alemtuzumab: Rare serious adverse events of a high-efficacy drug","volume":"26","author":"Hartung","year":"2020","journal-title":"Mult Scler"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib93","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib94","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01224-9_bib95","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fendo.2017.00254","article-title":"Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response","volume":"8","author":"Rotondi","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib96","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1017\/cjn.2015.48","article-title":"Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management","volume":"42","author":"Mahzari","year":"2015","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib97","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-022-01224-9_bib98","doi-asserted-by":"crossref","unstructured":"Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS: A whack-a-mole B-cell depletion strategy. Neurol Neuroimmunol Neuroinflamm. 2020;7(6).","DOI":"10.1212\/NXI.0000000000000868"},{"issue":"24","key":"10.1007\/s13311-022-01224-9_bib99","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1182\/blood-2011-08-371138","article-title":"A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis","volume":"118","author":"Cuker","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1352458518816612","article-title":"Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management","volume":"26","author":"Cuker","year":"2020","journal-title":"Mult Scler"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1352458514549398","article-title":"Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis","volume":"21","author":"Hartung","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01224-9_bib102","doi-asserted-by":"crossref","unstructured":"Coles AJ, Jones JL, Vermersch P, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit\/risk following review of trial and post-marketing data. Mult Scler. 2021:13524585211061335.","DOI":"10.1177\/13524585211061335"},{"issue":"18","key":"10.1007\/s13311-022-01224-9_bib103","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1212\/WNL.0000000000005409","article-title":"Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance","volume":"90","author":"Muraro","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib104","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/1352458519851219","article-title":"Emerging safety issues in alemtuzumab-treated MS patients","volume":"25","author":"Killestein","year":"2019","journal-title":"Mult Scler"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib106","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/annonc\/mdh114","article-title":"Coronary ischemia related to alemtuzumab therapy","volume":"15","author":"Basquiera","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib107","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"10.1007\/s13311-022-01224-9_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/119.1.225","article-title":"Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis","volume":"119","author":"Moreau","year":"1996","journal-title":"Brain"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1054-8807(02)00168-0","article-title":"Sudden death due to lymphomatous infiltration of the cardiac conduction system","volume":"12","author":"Ottaviani","year":"2003","journal-title":"Cardiovasc Pathol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib111","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000004950","article-title":"Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis","volume":"90","author":"Wehrum","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1007\/s13311-022-01224-9_bib112","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/WNL.0000000000003694","article-title":"Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab","volume":"88","author":"Barton","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib113","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00415-016-8306-x","article-title":"Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis","volume":"264","author":"Blasco","year":"2017","journal-title":"J Neurol"},{"issue":"22","key":"10.1007\/s13311-022-01224-9_bib114","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1212\/WNL.0000000000003379","article-title":"Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS","volume":"87","author":"Pfeuffer","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01224-9_bib115","doi-asserted-by":"crossref","unstructured":"Sauer EM, Schliep S, Manger B, et al. Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e488.","DOI":"10.1212\/NXI.0000000000000488"},{"issue":"13","key":"10.1007\/s13311-022-01224-9_bib116","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1352458518771276","article-title":"Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment","volume":"24","author":"Graf","year":"2018","journal-title":"Mult Scler"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib117","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.3390\/ijms160714669","article-title":"Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis\u2013report of two cases","volume":"16","author":"Rau","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1007\/s13311-022-01224-9_bib118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2018.05.014","article-title":"Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis","volume":"24","author":"Canham","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib119","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/1352458517729766","article-title":"Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab","volume":"24","author":"Meunier","year":"2018","journal-title":"Mult Scler"},{"issue":"18","key":"10.1007\/s13311-022-01224-9_bib120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1212\/WNL.0000000000005420","article-title":"Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab","volume":"90","author":"Saarela","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib121","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1352458517693440","article-title":"Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome","volume":"23","author":"Brownlee","year":"2017","journal-title":"Mult Scler"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib122","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1352458516688350","article-title":"Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab","volume":"23","author":"Clerico","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib123","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12020-010-9405-6","article-title":"Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism","volume":"39","author":"Berker","year":"2011","journal-title":"Endocrine"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ncl.2018.09.007","article-title":"Management of demyelinating disorders in pregnancy","volume":"37","author":"Kaplan","year":"2019","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-022-01224-9_bib125","doi-asserted-by":"crossref","unstructured":"Oh J, Achiron A, Chambers S, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program. Neurology. 2016;86:S24.008.","DOI":"10.1212\/WNL.86.16_supplement.S24.008"},{"key":"10.1007\/s13311-022-01224-9_bib126","doi-asserted-by":"crossref","unstructured":"Oh J, Achiron A, Celius EG, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146.","DOI":"10.1016\/j.msard.2020.102146"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib127","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: Association of British Neurologists guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib128","unstructured":"LEMTRADA (Alemtuzumab) Injection, for Intravenous Use. Full Prescribing Information. [cited 2021 October 25]; Available from: https:\/\/products.sanofi.us\/Lemtrada\/Lemtrada.pdf."},{"issue":"10","key":"10.1007\/s13311-022-01224-9_bib129","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-022-01224-9_bib131","doi-asserted-by":"crossref","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study. J Neuroimmunol. 2021;361:577746.","DOI":"10.1016\/j.jneuroim.2021.577746"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib132","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib133","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.09.003","article-title":"Targeting B cells in treatment of autoimmunity","volume":"43","author":"Franks","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1007\/s13311-022-01224-9_bib134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J Res Med Sci"},{"issue":"20","key":"10.1007\/s13311-022-01224-9_bib135","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib136","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib137","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib138","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1007\/s13311-022-01224-9_bib139","article-title":"Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis","volume":"12","author":"Tobias","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib141","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib142","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib143","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib144","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib145","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2017.12.005","article-title":"Severe neutropenia after rituximab-treatment of multiple sclerosis","volume":"20","author":"Rissanen","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1007\/s13311-022-01224-9_bib147","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2019","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01224-9_bib148","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"16","key":"10.1007\/s13311-022-01224-9_bib149","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: Increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01224-9_bib151","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1007\/s13311-022-01224-9_bib152","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2010-0106","article-title":"Hepatitis B reactivation and rituximab in the oncology practice","volume":"15","author":"Villadolid","year":"2010","journal-title":"Oncologist"},{"key":"10.1007\/s13311-022-01224-9_bib153","unstructured":"European Medical Agency. Mabthera summary of product characteristics. 2009."},{"issue":"5","key":"10.1007\/s13311-022-01224-9_bib154","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01224-9_bib155","doi-asserted-by":"crossref","unstructured":"Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.","DOI":"10.1212\/NXI.0000000000000453"},{"key":"10.1007\/s13311-022-01224-9_bib156","doi-asserted-by":"crossref","unstructured":"Klink DT, van Elburg RM, Schreurs MW, et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:271363.","DOI":"10.1155\/2008\/271363"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib157","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/kex039","article-title":"Low level of Rituximab in human breast milk in a patient treated during lactation","volume":"56","author":"Bragnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib158","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/toxsci\/kfq316","article-title":"Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys","volume":"119","author":"Vaidyanathan","year":"2011","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-022-01224-9_bib160","doi-asserted-by":"crossref","unstructured":"Kornek B, Leutmezer F, Rommer PS, et al. B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients. Ann Neurol. 2022.","DOI":"10.1002\/ana.26309"},{"key":"10.1007\/s13311-022-01224-9_bib161","doi-asserted-by":"crossref","unstructured":"Achtnichts L, Jakopp B, Oberle M, et al. Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines (Basel). 2021;9(12).","DOI":"10.3390\/vaccines9121470"},{"key":"10.1007\/s13311-022-01224-9_bib162","doi-asserted-by":"crossref","unstructured":"Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021.","DOI":"10.1101\/2021.06.23.21259389"},{"key":"10.1007\/s13311-022-01224-9_bib163","doi-asserted-by":"crossref","unstructured":"Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021.","DOI":"10.1001\/jamaneurol.2021.3599"},{"issue":"11","key":"10.1007\/s13311-022-01224-9_bib164","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1007\/s13311-022-01224-9_bib165","unstructured":"Ocrelizumab (Ocrevus) for MS. Med Lett Drugs Ther. 2017;59(1523):98\u2013101."},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"10.1007\/s13311-022-01224-9_bib167","doi-asserted-by":"crossref","unstructured":"Gingele S, Jacobus TL, Konen FF, et al. Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients. Cells. 2018;8(1).","DOI":"10.3390\/cells8010012"},{"key":"10.1007\/s13311-022-01224-9_bib168","unstructured":"European Medical Agency. Ocrevus summary of product characteristics. 2018"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib169","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib170","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Havrdova","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1007\/s13311-022-01224-9_bib171","doi-asserted-by":"crossref","unstructured":"Hartung HP; ENSEMBLE Steering Committee members and study investigators. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e807.","DOI":"10.1212\/NXI.0000000000000807"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib172","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"10.1007\/s13311-022-01224-9_bib174","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"10.1007\/s13311-022-01224-9_bib175","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01224-9_bib176","doi-asserted-by":"crossref","unstructured":"Hauser S, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis, in ECTRIMS. 2021:Vienna.","DOI":"10.1212\/WNL.0000000000012700"},{"issue":"13","key":"10.1007\/s13311-022-01224-9_bib177","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib178","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01224-9_bib179","doi-asserted-by":"crossref","unstructured":"Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).","DOI":"10.1212\/NXI.0000000000000723"},{"issue":"14","key":"10.1007\/s13311-022-01224-9_bib180","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01224-9_bib181","doi-asserted-by":"crossref","unstructured":"Guerrieri S, Lazzarin S, Zanetta C, et al. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol. 2022;269(1):39-43.","DOI":"10.1007\/s00415-021-10663-x"},{"key":"10.1007\/s13311-022-01224-9_bib182","doi-asserted-by":"crossref","unstructured":"Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021.","DOI":"10.1001\/jamaneurol.2021.3609"},{"key":"10.1007\/s13311-022-01224-9_bib183","doi-asserted-by":"crossref","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(5).","DOI":"10.1212\/NXI.0000000000001035"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib184","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s42466-021-00158-5","article-title":"Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis","volume":"3","author":"Pompsch","year":"2021","journal-title":"Neurol Res Pract"},{"key":"10.1007\/s13311-022-01224-9_bib185","doi-asserted-by":"crossref","unstructured":"Iannetta M, Landi D, Cola G, et al. B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications. Front Immunol. 2021;12:796482.","DOI":"10.3389\/fimmu.2021.796482"},{"key":"10.1007\/s13311-022-01224-9_bib186","doi-asserted-by":"crossref","unstructured":"Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.","DOI":"10.1016\/j.msard.2021.103251"},{"issue":"18","key":"10.1007\/s13311-022-01224-9_bib187","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"7","key":"10.1007\/s13311-022-01224-9_bib188","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1007\/s13311-022-01224-9_bib189","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13543784.2018.1459560","article-title":"Ublituximab for the treatment of CD20 positive B-cell malignancies","volume":"27","author":"Babiker","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1007\/s13311-022-01224-9_bib190","unstructured":"European Medical Agency. Kesimpta summary of product characteristics. 2021."},{"key":"10.1007\/s13311-022-01224-9_bib191","doi-asserted-by":"crossref","unstructured":"Smith P, Huck C, Schmid C, et al. Ofatumumab differs from rituximab by effectively targeting lymph node B cells and achieving faster post-treatment repletion (S24.003). Neurology. 2017;88(16 Supplement):S24.003.","DOI":"10.1212\/WNL.88.16_supplement.S24.003"},{"issue":"6","key":"10.1007\/s13311-022-01224-9_bib192","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01224-9_bib193","doi-asserted-by":"crossref","unstructured":"Bellot M, Bagger M, Horvat C, et al. Effect of ofatumumab on pregnancy, parturition and lactation in cynomolgus monkeys (2265). Neurology. 2021;96.","DOI":"10.1212\/WNL.96.15_supplement.2265"},{"key":"10.1007\/s13311-022-01224-9_bib194","unstructured":"Pregnancy Outcomes. 2021 [cited 2021 27 October]; Available from: https:\/\/www.ofatumumabinfo.com\/en\/pregnancy."},{"key":"10.1007\/s13311-022-01224-9_bib195","doi-asserted-by":"crossref","unstructured":"LaHue SC, Anderson A, Krysko KM, et al. Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).","DOI":"10.1212\/NXI.0000000000000769"},{"key":"10.1007\/s13311-022-01224-9_bib196","doi-asserted-by":"crossref","unstructured":"Krysko KM, LaHue SC, Anderson A, et al. Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm. 2020;7(1).","DOI":"10.1212\/NXI.0000000000000637"},{"issue":"1","key":"10.1007\/s13311-022-01224-9_bib197","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2013.240","article-title":"Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion","volume":"28","author":"Le Garff-Tavernier","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib198","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.14447","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial","volume":"176","author":"Sharman","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1007\/s13311-022-01224-9_bib199","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1007\/s13311-022-01224-9_bib200","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01224-9_bib201","unstructured":"Steinman L, Fox E, Hartung HP, et al. Phase 3 results of the ULTIMATE I & II global studies: ublituximab versus teriflunomide in relapsing multiple sclerosis, in ECTRIMS. 2021: Vienna."},{"key":"10.1007\/s13311-022-01224-9_bib202","unstructured":"Steinman L, Alvarez E, Fox E, et al. Ublituximab is associated with significant improvement in the multiple sclerosis functional composite (MSFC): results from the Phase 3 ULTIMATE I & II studies, in ECTRIMS. 2021: Vienna."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01224-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:35Z","timestamp":1761807095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":202,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011017"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01224-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01224-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}